TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT05357794

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing Brentuximab vedotin for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Brentuximab vedotin (DRUG): Given by Vein (IV)

Drugs / treatments
Brentuximab vedotin
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT05357794

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is testing Brentuximab vedotin for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Brentuximab vedotin (DRUG): Given by Vein (IV)

Drugs / treatments: Brentuximab vedotin

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 30 patients

Primary endpoint: To establish the overall response rate (ORR)

Ages: 18 Years to —

Start date: 2022-10-13 | Est. completion: 2027-01-30

Locations

1 US sites · 1 total

Texas

Contact

Bouthaina Dabaja, MD | bdabaja@mdanderson.org | (713) 563-2406

Sponsor: M.D. Anderson Cancer Center (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05357794

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.